1
|
Li D, Cui R, Xu S, Liu Y. Synergism of cisplatin-oleanolic acid co-loaded hybrid nanoparticles on gastric carcinoma cells for enhanced apoptosis and reversed multidrug resistance. Drug Deliv 2020; 27:191-199. [PMID: 31924110 PMCID: PMC7006694 DOI: 10.1080/10717544.2019.1710622] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Revised: 12/26/2019] [Accepted: 12/27/2019] [Indexed: 12/11/2022] Open
Abstract
Combined administration of different drugs is a widely acknowledged approach for effective cancer therapy. However, the limited targeting, as well as inferior drug loading capacities of current drug delivery systems (DDS), are still the bottleneck for better performance in cancer treatment. Herein, we successfully developed a cancer cell membrane (CM) decorated calcium carbonate (CC) hybrid nanoparticles (HN) for the co-delivery of cisplatin (CDDP) and oleanolic acid (OA). The physicochemical property of HN/CDDP/OA was evaluated, which revealed that the as-prepared DDS was core-shell structured and well-dispersed nanoparticles with size around 100 nm. The HN/CDDP/OA showed high stability and biocompatibility with pH-responsive drug release. Moreover, the CM modification in HN also demonstrated highly elevated tumor-homing nature than bare CC. Finally, the feasibility of HN/CDDP/OA in the treatment of gastric cancer (MGC-803 cell line) was assessed. HN/CDDP/OA showed better performance than mono systems with enhanced apoptosis and capable of reversing multidrug resistance (MDR) of cancer cells.
Collapse
Affiliation(s)
- Danyang Li
- Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Ruixue Cui
- Department of Medical Oncology, Tianjin Union Medical Center, Tianjin, China
| | - Shuning Xu
- Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Ying Liu
- Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| |
Collapse
|
2
|
Mierina I, Vilskersts R, Turks M. Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research. Curr Med Chem 2020; 27:1308-1336. [PMID: 29848269 DOI: 10.2174/0929867325666180530095657] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 02/28/2018] [Accepted: 04/05/2018] [Indexed: 02/07/2023]
Abstract
Birch-bark triterpenoids and their semi-synthetic derivatives possess a wide range of biological activities including cytotoxic effects on various tumor cell lines. However, due to the low solubility and bioavailability, their medicinal applications are rather limited. The use of various nanotechnology-based drug delivery systems is a rapidly developing approach to the solubilization of insufficiently bioavailable pharmaceuticals. Herein, the drug delivery systems deemed to be applicable for birch-bark triterpenoid structures are reviewed. The aforementioned disadvantages of birch-bark triterpenoids and their semi-synthetic derivatives can be overcome through their incorporation into organic nanoparticles, which include various dendrimeric systems, as well as embedding the active compounds into polymer matrices or complexation with carbohydrate nanoparticles without covalent bonding. Some of the known triterpenoid delivery systems consist of nanoparticles featuring inorganic cores covered with carbohydrates or other polymers. Methods for delivering the title compounds through encapsulation and emulsification into lipophilic media are also suitable. Besides, the birch-bark triterpenoids can form self-assembling systems with increased bio-availability. Even more, the self-assembling systems are used as carriers for delivering other chemotherapeutic agents. Another advantage besides increased bioavailability and anticancer activity is the reduced overall systemic toxicity in most of the cases, when triterpenoids are delivered with any of the carriers.
Collapse
Affiliation(s)
- Inese Mierina
- Institute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Riga, Latvia
| | - Reinis Vilskersts
- Latvian Institute of Organic Synthesis, Riga, Latvia; 3Faculty of Pharmacy, Riga Stradins University, Riga, Latvia.,Faculty of Pharmacy, Riga Stradins University, Riga, Latvia
| | - Māris Turks
- Institute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, Riga, Latvia
| |
Collapse
|
3
|
Curcio M, Farfalla A, Saletta F, Valli E, Pantuso E, Nicoletta FP, Iemma F, Vittorio O, Cirillo G. Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment. Molecules 2020; 25:E2102. [PMID: 32365886 PMCID: PMC7249046 DOI: 10.3390/molecules25092102] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 04/24/2020] [Accepted: 04/28/2020] [Indexed: 12/21/2022] Open
Abstract
Carbon nanostructures (CN) are emerging valuable materials for the assembly of highly engineered multifunctional nanovehicles for cancer therapy, in particular for counteracting the insurgence of multi-drug resistance (MDR). In this regard, carbon nanotubes (CNT), graphene oxide (GO), and fullerenes (F) have been proposed as promising materials due to their superior physical, chemical, and biological features. The possibility to easily modify their surface, conferring tailored properties, allows different CN derivatives to be synthesized. Although many studies have explored this topic, a comprehensive review evaluating the beneficial use of functionalized CNT vs G or F is still missing. Within this paper, the most relevant examples of CN-based nanosystems proposed for MDR reversal are reviewed, taking into consideration the functionalization routes, as well as the biological mechanisms involved and the possible toxicity concerns. The main aim is to understand which functional CN represents the most promising strategy to be further investigated for overcoming MDR in cancer.
Collapse
Affiliation(s)
- Manuela Curcio
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; (M.C.); (A.F.); (E.P.); (F.P.N.); (F.I.)
| | - Annafranca Farfalla
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; (M.C.); (A.F.); (E.P.); (F.P.N.); (F.I.)
| | - Federica Saletta
- Lowy Cancer Research Centre, Children’s Cancer Institute, UNSW Sydney, NSW 2031, Australia; (F.S.); (E.V.)
- School of Women’s and Children’s Health, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia
- ARC Centre of Excellence for Convergent BioNano Science and Technology, Australian Centre for NanoMedicine, UNSW Sydney, NSW 2052, Australia
| | - Emanuele Valli
- Lowy Cancer Research Centre, Children’s Cancer Institute, UNSW Sydney, NSW 2031, Australia; (F.S.); (E.V.)
- School of Women’s and Children’s Health, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia
| | - Elvira Pantuso
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; (M.C.); (A.F.); (E.P.); (F.P.N.); (F.I.)
| | - Fiore Pasquale Nicoletta
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; (M.C.); (A.F.); (E.P.); (F.P.N.); (F.I.)
| | - Francesca Iemma
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; (M.C.); (A.F.); (E.P.); (F.P.N.); (F.I.)
| | - Orazio Vittorio
- Lowy Cancer Research Centre, Children’s Cancer Institute, UNSW Sydney, NSW 2031, Australia; (F.S.); (E.V.)
- School of Women’s and Children’s Health, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia
- ARC Centre of Excellence for Convergent BioNano Science and Technology, Australian Centre for NanoMedicine, UNSW Sydney, NSW 2052, Australia
| | - Giuseppe Cirillo
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; (M.C.); (A.F.); (E.P.); (F.P.N.); (F.I.)
| |
Collapse
|
4
|
Chen D, Cai L, Guo Y, Chen J, Gao Q, Yang J, Li Y. Cancer Cell Membrane-Decorated Zeolitic-Imidazolate Frameworks Codelivering Cisplatin and Oleanolic Acid Induce Apoptosis and Reversed Multidrug Resistance on Bladder Carcinoma Cells. ACS OMEGA 2020; 5:995-1002. [PMID: 31984255 PMCID: PMC6977025 DOI: 10.1021/acsomega.9b02261] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 09/11/2019] [Indexed: 05/10/2023]
Abstract
Combination therapy is emerging as a preferable approach in cancer therapy with minimized side effects and elevated performance. Nevertheless, the poor targeting and drug loading of currently available drug delivery systems (DDSs) are the main difficulties to realize preferable combination therapy of cancer. As a result, a cancer cell membrane-decorated zeolitic-imidazolate framework hybrid nanoparticle (HP) was successfully constructed in our study to codeliver cisplatin (DDP) and oleanolic acid (OLA). Our results showed positive results of the platform (HP/DDP/OLA) for the treatment of bladder cancer (SW780). In detail, HP/DDP/OLA could enhance apoptosis while reverse multidrug resistance in SW780 cells than free drugs alone or monodelivery systems, which might be a suitable DDS for codelivery of different drugs with great promise.
Collapse
Affiliation(s)
- Dong Chen
- Department
of Urology, 2nd Affiliated Hospital of Fujian
Medical University, Quanzhou City 362000, Fujian Province, China
| | - Longbo Cai
- Department
of Urology, 2nd Affiliated Hospital of Fujian
Medical University, Quanzhou City 362000, Fujian Province, China
| | - Yihong Guo
- Department
of Urology, 2nd Affiliated Hospital of Fujian
Medical University, Quanzhou City 362000, Fujian Province, China
| | - Junyi Chen
- Department
of Urology, 2nd Affiliated Hospital of Fujian
Medical University, Quanzhou City 362000, Fujian Province, China
| | - Qiangli Gao
- Department
of Urology, The Affiliated Puren Hospital
of Wuhan University of Science and Technology, No. 1 Benxi Street, the Fourth Jianshe Road, Qingshan District, Wuhan 430080, China
| | - Junxian Yang
- Department
of Urology, The Affiliated Puren Hospital
of Wuhan University of Science and Technology, No. 1 Benxi Street, the Fourth Jianshe Road, Qingshan District, Wuhan 430080, China
| | - Yongfa Li
- Department
of Urology, The Affiliated Puren Hospital
of Wuhan University of Science and Technology, No. 1 Benxi Street, the Fourth Jianshe Road, Qingshan District, Wuhan 430080, China
| |
Collapse
|
5
|
Costanzo M, Malatesta M. Embedding cell monolayers to investigate nanoparticle-plasmalemma interactions at transmission electron microscopy. Eur J Histochem 2019; 63. [PMID: 30920191 PMCID: PMC6452225 DOI: 10.4081/ejh.2019.3026] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Accepted: 03/26/2019] [Indexed: 12/23/2022] Open
Abstract
Transmission electron microscopy is the technique of choice to visualize the spatial relationships between nanoconstructs and cells and especially to monitor the uptake process of nanomaterials. It is therefore crucial that the cell surface be preserved in its integrity, to obtain reliable ultrastructural evidence: the plasmalemma represents the biological barrier the nanomaterials have to cross, and the mode of membrane-nanoconstruct interaction is responsible for the intracellular fate of the nanomaterials. In this paper, we describe a simple and inexpensive method to process cell monolayers for ultrastructural morphology and immunocytochemistry, ensuring consistent preservation of the cell surface and of the occurring interactions with nanoparticles of different chemical composition.
Collapse
Affiliation(s)
- Manuela Costanzo
- University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Section of Anatomy and Histology.
| | | |
Collapse
|
6
|
Singh MS, Tammam SN, Shetab Boushehri MA, Lamprecht A. MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res 2017; 126:2-30. [PMID: 28760489 DOI: 10.1016/j.phrs.2017.07.023] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 06/29/2017] [Accepted: 07/26/2017] [Indexed: 01/02/2023]
Abstract
Multidrug resistance (MDR) is associated with a wide range of pathological changes at different cellular and intracellular levels. Nanoparticles (NPs) have been extensively exploited as the carriers of MDR reversing payloads to resistant tumor cells. However, when properly formulated in terms of chemical composition and physicochemical properties, NPs can serve as beyond delivery systems and help overcome MDR even without carrying a load of chemosensitizers or MDR reversing molecular cargos. Whether serving as drug carriers or beyond, a wise design of the nanoparticulate systems to overcome the cellular and intracellular alterations underlying the resistance is imperative. Within the current review, we will initially discuss the cellular changes occurring in resistant cells and how such changes lead to chemotherapy failure and cancer cell survival. We will then focus on different mechanisms through which nanosystems with appropriate chemical composition and physicochemical properties can serve as MDR reversing units at different cellular and intracellular levels according to the changes that underlie the resistance. Finally, we will conclude by discussing logical grounds for a wise and rational design of MDR reversing nanoparticulate systems to improve the cancer therapeutic approaches.
Collapse
Affiliation(s)
- Manu S Singh
- Department of Pharmaceutical Technology and Biopharmceutics, University of Bonn, Germany
| | - Salma N Tammam
- Department of Pharmaceutical Technology and Biopharmceutics, University of Bonn, Germany; Department of Pharmaceutical Technology, German University of Cairo, Egypt
| | | | - Alf Lamprecht
- Department of Pharmaceutical Technology and Biopharmceutics, University of Bonn, Germany; Laboratory of Pharmaceutical Engineering (EA4267), University of Franche-Comté, Besançon, France.
| |
Collapse
|